M&A / Deals Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide Pharmaceutical Business ReviewThe agreement covers Hanmi's candidate that uses its LAPSCOVERY long-acting platform technology.Metabolic & GLP-1Read full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaceutical Business Review The agreement covers Hanmi’s candidate that uses its LAPSCOVERY long-acting platform technology. Metabolic & GLP-1 Read full story Post navigation Previous: FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapyNext: ASCO: Summit reached with China lung data but new climb begins to prove global benefit Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026